AIM ImmunoTech Inc (AMEX:AIM)

North American company
add to virtual portfolio
trade
This share can be held in
Trading AccountISAJISASIPP

Share Price Chart

- Chart currently unavailable -

Market Info - AIM

  • Market Open Price0.00
  • Previous Close0.00
  • Volume-
  • 52w Low/High-
  • Last Trade Price0.00
  • Bid/Ask Price0.00

Company Info - AIM

  • Market Cap$84.940m
  • SymbolAMEX:AIM
  • IndustryHealthcare
  • SectorBiotechnology
  • Currency
  • ISINUS00901B1052

Company Profile

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.Hemispherx Biopharma Inc is a specialty pharmaceutical company. It is primarily engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based disorders.

Latest AIM news

Currently there for this company. Visit our news hub for other news .